Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Singular Genomics Systems, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/09/2023 |
8-K
| Quarterly results|
Docs:
|
"### EX-99.1 Singular Genomics Systems, Inc. Statements of Operations Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Revenue $ 505 $ - $ 1,368 $ - Cost of revenue 597 - 1,404 - Gross margin - - Operating expenses: Research and development 12,624 12,061 24,854 22,707 Selling, general and administrative 14,887 12,182 28,091 23,556 Total operating expenses 27,511 24,243 52,945 46,263 Loss from operations Other income : Interest expense Interest and other income 2,295 428 4,299 584 Total other income 2,025 261 3,770 275 Net loss $ $ $ $ Net loss per share: Basic and diluted net loss per share $ $ $ $ Weighted-average shares used to compute basic and diluted net loss per share 72,510,020 70,779,326 72,218,280 70,893,059 EX-99.1 Singular Genomics Systems, Inc. Bala..." |
|
| 08/08/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/20/2023 |
8-K
| Quarterly results |
| 05/09/2023 |
8-K
| Quarterly results|
Docs:
|
"Singular Genomics Systems, Inc. Statements of Operations Three Months Ended March 31, 2023 2022 Revenue $ 863 $ - Cost of revenue 807 - Gross margin 56 - Operating expenses: Research and development 12,230 10,645 Selling, general and administrative 13,204 11,375 Total operating expenses 25,434 22,020 Loss from operations Other income : Interest expense Interest and other income 2,004 156 Total other income 1,745 14 Net loss $ $ Net loss per share: Basic and diluted net loss per share $ $ Weighted-average shares used to compute basic and diluted net loss per share 71,926,412 71,011,041 EX-99.1 Singular Genomics Systems, Inc. Balance Sheets March 31, December 31, 2023 2022 Assets Current assets: Cash and cash equivalents $ 129,283 $ 74,266 Short-term investments 96,790 170,310 Accounts rec..." |
|
| 03/02/2023 |
8-K
| Quarterly results|
Docs:
|
"Singular Genomics Systems, Inc. Statements of Operations Three Months Ended December 31, Year Ended December 31, 2022 2021 2022 2021 Revenue $ 765 $ - $ 765 $ - Cost of revenue 789 - 789 - Gross margin - - Operating expenses: Research and development 10,760 9,455 46,199 32,655 Selling, general and administrative 11,746 10,218 47,264 28,624 Total operating expenses 22,506 19,673 93,463 61,279 Loss from operations Other income : Interest expense Change in fair value of convertible promissory notes" |
|
| 01/09/2023 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits I... |
| 11/07/2022 |
8-K
| Financial Statements and Exhibits Interactive Data|
Docs:
|
"Singular Genomics Systems, Inc. Condensed Statements of Operations Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Operating expenses: Research and development $ 12,732 $ 8,910 $ 35,439 $ 23,200 Selling, general and administrative 11,962 8,551 35,518 18,406 Total operating expenses 24,694 17,461 70,957 41,606 Loss from operations Other income : Interest and other income 1,115 84 1,699 628 Interest expense Change in fair value of convertible promissory notes" |
|
| 10/04/2022 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
| 08/09/2022 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Singular Genomics Systems, Inc. Condensed Statements of Operations Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Operating expenses: Research and development $ 12,061 $ 7,682 $ 22,707 $ 14,289 Selling, general and administrative 12,182 6,201 23,556 9,855 Total operating expenses 24,243 13,883 46,263 24,144 Loss from operations Other income : Interest and other income 428 413 584 543 Interest expense Change in fair value of convertible promissory notes - - Change in fair value of warrant liability - 22 - Net loss $ $ $ $ Net loss per share: Basic and diluted net loss per share $ $ $ $ Weighted-average shares used to compute basic and diluted net loss per share 70,779,326 31,628,921 70,893,059 21,696,142 Singular Genomics Systems, Inc. Condensed Balance Sheet..." |
|
| 07/25/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/19/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 06/02/2022 |
8-K
| Quarterly results |
| 05/10/2022 |
8-K
| Quarterly results |
| 04/26/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/02/2022 |
8-K
| Quarterly results |
| 01/26/2022 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...|
Docs:
|
"SERIES A COMMON STOCK EQUIVALENT CONVERTIBLE PREFERRED STOCK Section 1. Definitions. For the purposes hereof, the following terms shall have the following meanings: “Affiliate” means, with respect to any specified Person, any other Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with such specified Person, as such terms are used in and construed under Rule 144 under the Securities Act. For this purpose, “control” means the possession, directly or indirectly, of the power to direct or cause the direction of management or policies of a Person, whether through the ownership of securities or partnership or other ownership interests, by contract or otherwise. With respect to a Holder, any...",
"EXCHANGE AGREEMENT This EXCHANGE AGREEMENT , dated as of January 26, 2022, is entered into by and among Singular Genomics Systems, Inc., a Delaware corporation and Deerfield Private Design Fund IV, L.P. . RECITALS: A. The Holder owns the number of shares of the Company’s common stock, par value $0.0001 per share , set forth opposite the Holder’s name on Schedule A hereto. B. The board of directors of the Company has authorized the creation of a new series of preferred stock denominated as Series A Common Stock Equivalent Convertible Preferred Stock with the preferences, rights and limitations described in the Certificate of Designation of Preferences, Rights and Limitations of Series A Common Equivalent Preferred Stock, in the form attached hereto as Exhibit A . The Certificate of Designat..." |
|
| 01/20/2022 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
| 01/10/2022 |
8-K
| Regulation FD Disclosure Interactive Data |
| 01/06/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/16/2021 |
8-K
| Quarterly results |
| 11/09/2021 |
8-K
| Quarterly results|
Docs:
|
"Singular Genomics Systems, Inc. Statements of Operations Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Operating expenses: Research and development $ 8,910 $ 6,080 $ 23,200 $ 15,431 Selling, general and administrative 8,551 1,698 18,406 4,518 Total operating expenses 17,461 7,778 41,606 19,949 Loss from operations Other income : Interest income 91 76 223 444 Interest expense Change in fair value of convertible promissory notes - - - Change in fair value of warrant liability - Other income 20 405 24 Net loss $ $ $ $ Net loss per share: Basic and diluted net loss per share $ $ $ $ Weighted-average shares used to compute basic and diluted net loss per share 71,721,861 10,726,496 38,553,685 10,507,732 Singular Genomics Systems, Inc. Condensed Balanc..." |
|
| 10/04/2021 |
8-K
| Quarterly results |
| 08/31/2021 |
8-K
| Quarterly results |
| 08/11/2021 |
8-K
| Quarterly results |
| 08/03/2021 |
8-K
| Quarterly results |
| 06/01/2021 |
8-K
| Quarterly results |
|
|